Global Budesonide Inhaler Market Size, by Dosage Form (Aerosol, Dry Powder), by Strength (0.25 mg, 0.5 mg) & Region - Key Manufacturers, Analysis, Growth Trends, and Forecast till 2026

  • Category : Healthcare and Pharma
  • |
  • ID : 1139774
  • |
  • Publishe Date : July-2019
  • |
  • No of Pages: 121
  • |
  • Publisher : Intellectual Research Partners

The Global Budesonide Inhaler Market was estimated to be valued at USD XX million in 2018 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2019 to 2026. Increasing prevalence of respiratory problems is driving the market growth. Wherein the side effect of the drug might restraint the market growth.

The global budesonide inhaler market is primarily segmented based on dosage form, strength and regions.

On the basis of dosage form, the market is split into:
* Aerosol
* Dry Powder
* Suspension
* Spray

On the basis of strength, the market is split into:
* 0.25 mg
* 0.5 mg
* 1 mg

Moreover, the market is classified based on region and countries as follows:
* North America- U.S., Canada
* Europe- U.K., France, Germany, Italy and Rest of Europe
* Asia-Pacific- China, Japan, India and Rest of Asia Pacific
* South America- Brazil, Mexico and Rest of South America
* Middle East & Africa- South Africa, Saudi Arabia and Rest of Middle East & Africa

Key Market Players:
The key players profiled in the market include:
* Pfizer Inc.
* Cipla Limited
* Lupin Limited
* Cosmo Pharmaceuticals
* Sandoz
* AstraZeneca plc
* Orion Oyj
* Synmosa Biopharma Corp.
* Sun Pharmaceutical Industries Limited
* Nephron Pharmaceuticals Corporation

These enterprises are focusing on growth strategies, such as new product launches, expansions, acquisitions, and agreements & partnerships to expand their operations across the globe.

Key Benefits of the Report:
* Global, regional, country, dosage form, strength and market size and their forecast from 2015-2026
* Identification and detailed analysis on key market dynamics, such as, drivers, restraints, opportunities, and challenges influencing growth of the market
* Detailed analysis on industry outlook with market specific PESTLE, and supply chain to better understand the market and build expansion strategies
* Identification of key market players and comprehensively analyze their market share and core competencies, detailed financial positions, key products, and unique selling points
* Analysis on key players’ strategic initiatives and competitive developments, such as joint ventures, mergers, and new product launches in the market
* Expert interviews and their insights on market shift, current and future outlook, and factors impacting vendors’ short term and long term strategies
* Detailed insights on emerging regions dosage form, strength and options with qualitative and quantitative information and facts

Target Audience:
* Budesonide Inhaler Manufacturers
* Traders, Importers, and Exporters
* Raw Material Suppliers and Distributors
* Research and Consulting Firms
* Government and Research Organizations
* Associations and Industry Bodies

Research Methodology:
The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective, such as, analyst reports of investment banks. The secondary research is the primary base of our study wherein we conducted extensive data mining, referring to verified data sources, such as, white papers, government and regulatory published articles, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factors, recent investments, market dynamics including technical growth scenario, consumer behavior, and end use trends and dynamics, and production capacity were taken into consideration. Different weightages have been assigned to these parameters and quantified their market impacts using the weighted average analysis to derive the market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs), which typically include:
* Manufacturers
* Suppliers
* Distributors
* Government Body & Associations
* Research Institutes

TABLE OF CONTENTS

1. Introduction

2. Research Methodology

3. Executive Summary

4. Global Budesonide Inhaler Market Overview
4.1. Market Segmentation & Scope
4.2. Market Trends
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Supply Chain Analysis
4.3. Global Budesonide Inhaler Market - Porter\'s Five Forces Analysis
4.4. Global Budesonide Inhaler Market - PESTEL Analysis


5. Global Budesonide Inhaler Market, by Dosage Form
5.1. Global Budesonide Inhaler Market, Size and Forecast, 2015-2026
5.2. Global Budesonide Inhaler Market by Aerosol, 2015-2026
5.2.1. Key driving factors, trends and opportunities
5.2.2. Market size and forecast, 2015-2026
5.3. Global Budesonide Inhaler Market by Dry Powder, 2015-2026
5.3.1. Key driving factors, trends and opportunities
5.3.2. Market size and forecast, 2015-2026
5.4. Global Budesonide Inhaler Market by Suspension, 2015-2026
5.4.1. Key driving factors, trends and opportunities
5.4.2. Market size and forecast, 2015-2026
5.5. Global Budesonide Inhaler Market by Spray, 2015-2026
5.5.1. Key driving factors, trends and opportunities
5.5.2. Market size and forecast, 2015-2026

6. Global Budesonide Inhaler Market, by Strength
6.1. Global Budesonide Inhaler Market, Size and Forecast, 2015-2026
6.2. Global Budesonide Inhaler Market by 0.25 mg, 2015-2026
6.2.1. Key driving factors, trends and opportunities
6.2.2. Market size and forecast, 2015-2026
6.3. Global Budesonide Inhaler Market by 0.5 mg, 2015-2026
6.3.1. Key driving factors, trends and opportunities
6.3.2. Market size and forecast, 2015-2026
6.4. Global Budesonide Inhaler Market by 1 mg, 2015-2026
6.4.1. Key driving factors, trends and opportunities
6.4.2. Market size and forecast, 2015-2026

7. Global Budesonide Inhaler Market by Region
7.1. Budesonide Inhaler Market Regional Analysis, 2015-2026
7.2. Global Budesonide Inhaler Market Revenue (USD Million) by Region, 2015-2026
7.3. North America Budesonide Inhaler Market, 2015-2026
7.3.1. North America Budesonide Inhaler Market Size and Forecast, 2015-2026
7.3.2. North America Budesonide Inhaler Market by Country, 2015-2026
7.3.2.1. U.S. Budesonide Inhaler Market, 2015-2026
7.3.2.2. Canada Budesonide Inhaler Market, 2015-2026
7.4. Europe Budesonide Inhaler Market, 2015-2026
7.4.1. Europe Budesonide Inhaler Market Size and Forecast, 2015-2026
7.4.2. Europe Budesonide Inhaler Market by Country, 2015-2026
7.4.2.1. Germany Budesonide Inhaler Market, 2015-2026
7.4.2.2. France Budesonide Inhaler Market, 2015-2026
7.4.2.3. Italy Budesonide Inhaler Market, 2015-2026
7.4.2.4. UK Budesonide Inhaler Market, 2015-2026
7.4.2.5. Spain Budesonide Inhaler Market, 2015-2026
7.4.2.6. Rest of Europe Budesonide Inhaler Market, 2015-2026
7.5. Asia Pacific Budesonide Inhaler Market, 2015-2026
7.5.1. Asia Pacific Budesonide Inhaler Market Size and Forecast, 2015-2026
7.5.2. Asia Pacific Budesonide Inhaler Market by Country, 2015-2026
7.5.2.1. Japan Budesonide Inhaler Market, 2015-2026
7.5.2.2. China Budesonide Inhaler Market, 2015-2026
7.5.2.3. India Budesonide Inhaler Market, 2015-2026
7.5.2.4. Rest of Asia Pacific Budesonide Inhaler Market, 2015-2026
7.6. South America Budesonide Inhaler Market, 2015-2026
7.6.1. South America Budesonide Inhaler Market Size and Forecast, 2015-2026
7.6.2. South America Budesonide Inhaler Market by Country, 2015-2026
7.6.2.1. Mexico Budesonide Inhaler Market, 2015-2026
7.6.2.2. Brazil Budesonide Inhaler Market, 2015-2026
7.6.2.3. Rest of South America Budesonide Inhaler Market, 2015-2026
7.7. Middle East & Africa Budesonide Inhaler Market, 2015-2026
7.7.1. Middle East & Africa Budesonide Inhaler Market Size and Forecast, 2015-2026
7.7.2. Middle East & Africa Budesonide Inhaler Market by Country, 2015-2026
7.7.2.1. Saudi Arabia Budesonide Inhaler Market, 2015-2026
7.7.2.2. South Africa Budesonide Inhaler Market, 2015-2026
7.7.2.3. Rest of Middle East & Africa Budesonide Inhaler Market, 2015-2026

8. Competitive Landscape
8.1. Introduction
8.2. Market Share Analysis/Top Player Positioning, 2018

9. Company Profiles
9.1. Pfizer Inc.
9.1.1. Company Overview
9.1.2. Financial Overview
9.1.3. Product Benchmarking
9.1.4. Key Developments
9.2. Cipla Limited
9.2.1. Company Overview
9.2.2. Financial Overview
9.2.3. Product Benchmarking
9.2.4. Key Developments
9.3. Lupin Limited
9.3.1. Company Overview
9.3.2. Financial Overview
9.3.3. Product Benchmarking
9.3.4. Key Developments
9.4. Cosmo Pharmaceuticals
9.4.1. Company Overview
9.4.2. Financial Overview
9.4.3. Product Benchmarking
9.4.4. Key Developments
9.5. Sandoz
9.5.1. Company Overview
9.5.2. Financial Overview
9.5.3. Product Benchmarking
9.5.4. Key Developments
9.6. AstraZeneca plc
9.6.1. Company Overview
9.6.2. Financial Overview
9.6.3. Product Benchmarking
9.6.4. Key Developments
9.7. Orion Oyj
9.7.1. Company Overview
9.7.2. Financial Overview
9.7.3. Product Benchmarking
9.7.4. Key Developments
9.8. Synmosa Biopharma Corp.
9.8.1. Company Overview
9.8.2. Financial Overview
9.8.3. Product Benchmarking
9.8.4. Key Developments
9.9. Sun Pharmaceutical Industries Limited
9.9.1. Company Overview
9.9.2. Financial Overview
9.9.3. Product Benchmarking
9.9.4. Key Developments
9.10. Nephron Pharmaceuticals Corporation
9.10.1. Company Overview
9.10.2. Financial Overview
9.10.3. Product Benchmarking
9.10.4. Key Developments

10. Key Insights

Content are not available

Choose License Type